Standard

Неврологические проявления у пациентов с новой коронавирусной инфекцией COVID-19. / Щербак, Сергей Григорьевич; Голота, Александр Сергеевич; КАМИЛОВА , ТАТЬЯНА АСКАРОВНА; Вологжанин, Дмитрий Александрович; Макаренко, Станислав Вячеславович.

In: Физическая и реабилитационная медицина, медицинская реабилитация, Vol. 4, No. 3, 02.10.2022, p. 154-180.

Research output: Contribution to journalReview articlepeer-review

Harvard

Щербак, СГ, Голота, АС, КАМИЛОВА , ТАТЬЯНААСКАРОВНА, Вологжанин, ДА & Макаренко, СВ 2022, 'Неврологические проявления у пациентов с новой коронавирусной инфекцией COVID-19', Физическая и реабилитационная медицина, медицинская реабилитация, vol. 4, no. 3, pp. 154-180. https://doi.org/10.36425/rehab109952

APA

Щербак, С. Г., Голота, А. С., КАМИЛОВА , ТАТЬЯНА. АСКАРОВНА., Вологжанин, Д. А., & Макаренко, С. В. (2022). Неврологические проявления у пациентов с новой коронавирусной инфекцией COVID-19. Физическая и реабилитационная медицина, медицинская реабилитация, 4(3), 154-180. https://doi.org/10.36425/rehab109952

Vancouver

Щербак СГ, Голота АС, КАМИЛОВА ТАТЬЯНААСКАРОВНА, Вологжанин ДА, Макаренко СВ. Неврологические проявления у пациентов с новой коронавирусной инфекцией COVID-19. Физическая и реабилитационная медицина, медицинская реабилитация. 2022 Oct 2;4(3):154-180. https://doi.org/10.36425/rehab109952

Author

Щербак, Сергей Григорьевич ; Голота, Александр Сергеевич ; КАМИЛОВА , ТАТЬЯНА АСКАРОВНА ; Вологжанин, Дмитрий Александрович ; Макаренко, Станислав Вячеславович. / Неврологические проявления у пациентов с новой коронавирусной инфекцией COVID-19. In: Физическая и реабилитационная медицина, медицинская реабилитация. 2022 ; Vol. 4, No. 3. pp. 154-180.

BibTeX

@article{676974e7421641beb6c3e24df4e7d145,
title = "Неврологические проявления у пациентов с новой коронавирусной инфекцией COVID-19",
abstract = "Most commonly, COVID-19 presents as a respiratory disease, but a growing body of clinical evidence shows that neurological symptoms and complications contribute significantly to the clinical spectrum of the disease, especially in patients with severe disease. The public health impact of the long-term (or even life-long) consequences of the disease may be much greater than the acute manifestations of SARS-CoV-2 infection. As the pandemic has evolved, the number of neurological manifestations as part of the clinical spectrum of the disease has increased. The diverse neurological manifestations of COVID-19 range from mild symptoms (myalgia, headache, fatigue, dizziness, anosmia, ageusia) to more severe manifestations such as encephalopathy, encephalitis, acute and chronic polyneuropathy. Neurological symptoms and complications of COVID-19 do not necessarily require direct infection of structures in the peripheral or central nervous system, but may occur secondary to a severe systemic reaction to SARS-CoV-2 infection outside the nervous system. The neurotoxicity of SARS-CoV-2 infection may be secondary to immune-mediated pathogenesis and coagulation dysfunction. To substantiate the therapeutic choice, it is necessary to study the pathophysiological processes and clinical trials.",
author = "Щербак, {Сергей Григорьевич} and Голота, {Александр Сергеевич} and КАМИЛОВА, {ТАТЬЯНА АСКАРОВНА} and Вологжанин, {Дмитрий Александрович} and Макаренко, {Станислав Вячеславович}",
year = "2022",
month = oct,
day = "2",
doi = "10.36425/rehab109952",
language = "русский",
volume = "4",
pages = "154--180",
journal = "Физическая и реабилитационная медицина, медицинская реабилитация",
issn = "2658-6843",
publisher = "Федеральный научно-клинический центр реаниматологии и реабилитологии",
number = "3",

}

RIS

TY - JOUR

T1 - Неврологические проявления у пациентов с новой коронавирусной инфекцией COVID-19

AU - Щербак, Сергей Григорьевич

AU - Голота, Александр Сергеевич

AU - КАМИЛОВА , ТАТЬЯНА АСКАРОВНА

AU - Вологжанин, Дмитрий Александрович

AU - Макаренко, Станислав Вячеславович

PY - 2022/10/2

Y1 - 2022/10/2

N2 - Most commonly, COVID-19 presents as a respiratory disease, but a growing body of clinical evidence shows that neurological symptoms and complications contribute significantly to the clinical spectrum of the disease, especially in patients with severe disease. The public health impact of the long-term (or even life-long) consequences of the disease may be much greater than the acute manifestations of SARS-CoV-2 infection. As the pandemic has evolved, the number of neurological manifestations as part of the clinical spectrum of the disease has increased. The diverse neurological manifestations of COVID-19 range from mild symptoms (myalgia, headache, fatigue, dizziness, anosmia, ageusia) to more severe manifestations such as encephalopathy, encephalitis, acute and chronic polyneuropathy. Neurological symptoms and complications of COVID-19 do not necessarily require direct infection of structures in the peripheral or central nervous system, but may occur secondary to a severe systemic reaction to SARS-CoV-2 infection outside the nervous system. The neurotoxicity of SARS-CoV-2 infection may be secondary to immune-mediated pathogenesis and coagulation dysfunction. To substantiate the therapeutic choice, it is necessary to study the pathophysiological processes and clinical trials.

AB - Most commonly, COVID-19 presents as a respiratory disease, but a growing body of clinical evidence shows that neurological symptoms and complications contribute significantly to the clinical spectrum of the disease, especially in patients with severe disease. The public health impact of the long-term (or even life-long) consequences of the disease may be much greater than the acute manifestations of SARS-CoV-2 infection. As the pandemic has evolved, the number of neurological manifestations as part of the clinical spectrum of the disease has increased. The diverse neurological manifestations of COVID-19 range from mild symptoms (myalgia, headache, fatigue, dizziness, anosmia, ageusia) to more severe manifestations such as encephalopathy, encephalitis, acute and chronic polyneuropathy. Neurological symptoms and complications of COVID-19 do not necessarily require direct infection of structures in the peripheral or central nervous system, but may occur secondary to a severe systemic reaction to SARS-CoV-2 infection outside the nervous system. The neurotoxicity of SARS-CoV-2 infection may be secondary to immune-mediated pathogenesis and coagulation dysfunction. To substantiate the therapeutic choice, it is necessary to study the pathophysiological processes and clinical trials.

UR - https://www.mendeley.com/catalogue/d791369f-ecfb-33c8-8478-b939f6b73667/

U2 - 10.36425/rehab109952

DO - 10.36425/rehab109952

M3 - Обзорная статья

VL - 4

SP - 154

EP - 180

JO - Физическая и реабилитационная медицина, медицинская реабилитация

JF - Физическая и реабилитационная медицина, медицинская реабилитация

SN - 2658-6843

IS - 3

ER -

ID: 101141197